Harpoon Therapeutics Announces Closing of Public Offering of Common Stock

Rhea-AI Summary

Harpoon Therapeutics has successfully concluded its public offering, selling 6,764,704 shares of common stock. This includes 882,352 shares from the underwriters' full exercise of their option, yielding approximately $115.0 million in gross proceeds. The offering is based on a previously filed shelf registration statement with the SEC. SVB Leerink and Piper Sandler led the offering's management.

Positive

• The offering raised approximately $115.0 million in gross proceeds.
• Funds will likely be used to advance Harpoon's therapeutic programs.

Negative

• Shareholder dilution may occur due to the large number of shares issued.

Underwriters Fully Exercise Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP) announced today the closing of its underwritten public offering of 6,764,704 shares of its common stock, which includes 882,352 shares sold upon the underwriters’ full exercise of their option to purchase additional shares, resulting in aggregate gross proceeds of approximately $115.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Harpoon Therapeutics.

SVB Leerink and Piper Sandler acted as joint bookrunning managers for the offering. Baird and Truist Securities acted as co-lead managers for the offering. Roth Capital Partners acted as co-manager for the offering.

The shares of common stock were offered pursuant to a “shelf” registration statement previously filed with and declared effective by the Securities and Exchange Commission (SEC). The offering is being made only by means of a prospectus supplement and accompanying prospectus, copies of which may be obtained from: SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132 or by email at syndicate@svbleerink.com or Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at prospectus@psc.com.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of a prospectus supplement and accompanying prospectus, which are a part of the effective registration statement.

Contacts:
Harpoon Therapeutics, Inc.
Georgia Erbez
Chief Financial Officer
650-443-7400
media@harpoontx.com

Westwicke ICR
Robert H. Uhl
Managing Director
858-356-5932
robert.uhl@westwicke.com

FAQ

What are the details of the Harpoon Therapeutics stock offering?

Harpoon Therapeutics offered 6,764,704 shares, including 882,352 from underwriters' exercised options, raising approximately $115.0 million.

Who managed the Harpoon Therapeutics public offering?

SVB Leerink and Piper Sandler acted as joint bookrunning managers, with Baird and Truist Securities as co-lead managers.

What does the completion of the offering mean for Harpoon's shareholders?

The completion of the offering may lead to shareholder dilution due to the increase in common stock available.

When was the Harpoon Therapeutics offering announced?

The offering was announced on January 11, 2021.